

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TIAN CHENG HOLDINGS LIMITED **天成控股有限公司**

(formerly known as Yue Kan Holdings Limited 裕勤控股有限公司)
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2110)

VOLUNTARY ANNOUNCEMENT – LAUNCH OF NEW BUSINESS ACTIVITY

This announcement is made by Tian Cheng Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of updating the shareholders of the Company (the “**Shareholders**”) and potential investors on the latest business development of the Group.

The Company has been exploring and identifying potential investment opportunities to develop and diversify the Group’s existing business portfolio with an aim to broaden the income sources of the Group. Leveraging on the expertise of the present board (the “**Board**”) of directors (the “**Directors**”) of the Company, the Board wishes to announce that the Group has recently established an indirect wholly-owned subsidiary of the Company in the PRC, with a primary focus in the research and development, manufacture and sale of class II medical devices controlled and administered under the Regulation on the Supervision and Administration of Medical Devices (醫療器械監督管理條例), as well the operation of medical care and wellness centres in the PRC (collectively, the “**New Business Activity**”). The New Business Activity will be led by Ms. Zheng Yanling and Mr. Zhao Dongquan, both executive Directors, who have accumulated experience in business management in the PRC and the development, operation and sale of medical devices respectively.

The Board is of the view that the launch of the New Business Activity presents an opportunity for the Group to diversify its existing business portfolio and takes advantage of the expertise and experience of the management of the Group. Further, driven by the increasing and aging population, the prevalence of chronic diseases, and the increased awareness and affordability of patients in the PRC, there is an increasing demand for high technology medical devices for diseases prevention and treatment in the PRC, creating potential for the development of the New Business Activity. The Company also considers that the New Business Activity is in line with the PRC’s ongoing healthcare policy “Healthy China 2030” (健康中國2030) promoting, among others, improving general healthcare in the PRC and domestic developed medical technology and devices. Hence, having considered the above, the Company is of the view that the launch of the New Business Activity will be in the interests of the Company and the Shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Tian Cheng Holdings Limited
Zheng Yanling
Chairman and Executive Director

Hong Kong, 30 June 2023

As at the date of this announcement, the Board comprises ten Directors, namely Ms. Zheng Yanling, Mr. Heung Yue Wing, Mr. Ouyang Jianwen, Mr. Luo Hao, Mr. Wong Yuk and Mr. Zhao Dongquan as executive Directors; Ms. Du Min as a non-executive Director; and Mr. Wan San Fai Vincent, Mr. Zhang Wenyong and Mr. Luo Sheng as independent non-executive Directors.